公开(公告)号：US07230084B2

公开(公告)日：2007-06-12

申请号：US10259853

申请日：2002-09-30

Applicant: Hans J. Hansen

Inventor： Hans J. Hansen

IPC: C07K16/00

CPC classification number: A61K51/1048 ,  A61K38/00 ,  A61K47/62 ,  A61K47/6893 ,  A61K51/0495 ,  A61K2039/507 ,  B82Y5/00 ,  C07K16/1045 ,  C07K16/14 ,  C07K16/18 ,  C07K16/242 ,  C07K16/2833 ,  C07K16/3007 ,  C07K16/4241 ,  C07K16/4258 ,  C07K16/4266 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/626

Abstract: Multivalent, multispecific molecules having at least one specificity for a pathogen and at least one specificity for the HLA class II invariant chain (Ii) are administered to induce clearance of the pathogen. In addition to pathogens, clearance of therapeutic or diagnostic agents, autoantibodies, anti-graft antibodies, and other undesirable compounds may be induced using the multivalent, multispecific molecules.

Abstract translation: 给予对病原体具有至少一种特异性和对HLA II类不变链（Ii）至少一种特异性的多价多特异性分子，以诱导病原体的清除。 除了病原体之外，还可以使用多价多特异性分子来诱导治疗或诊断剂，自身抗体，抗移植物抗体和其它不期望的化合物的清除。

公开(公告)号：US07201890B2

公开(公告)日：2007-04-10

申请号：US10086637

申请日：2002-03-04

Applicant: Milton D. Goldenberg

Inventor： Milton D. Goldenberg

IPC: A61K51/00 ,  A61K39/00

CPC classification number: A61K49/0058 ,  A61K47/6898 ,  A61K49/0036 ,  A61K51/1048 ,  A61K51/1072 ,  A61K51/1093 ,  A61K2121/00 ,  A61K2123/00 ,  B82Y5/00

Abstract: Methods are provided for close-range intraoperative, endoscopic and intravascular detection and treatment of lesions, including tumors and non-malignant lesions. The methods use antibody fragments or subfragments labeled with isotopic and non-isotopic agents. Also provided are methods for detection and treatment of lesions with photodynamic agents and methods of treating lesions with a protein conjugated to an agent capable of being activated to emit Auger electron or other ionizing radiation. Compositions and kits useful in the above methods are also provided.

Abstract translation: 提供方法用于近距离术中，内窥镜和血管内检测和治疗病变，包括肿瘤和非恶性病变。 该方法使用用同位素和非同位素标记的抗体片段或亚片段。 还提供了用光动力学试剂检测和治疗病变的方法以及用能够被活化以发射俄歇电子或其他电离辐射的药物缀合的蛋白质处理病变的方法。 还提供了在上述方法中有用的组合物和试剂盒。

公开(公告)号：US20060140858A1

公开(公告)日：2006-06-29

申请号：US10514632

申请日：2003-05-16

Applicant: David Goldenberg ,  Hans Hansen ,  Shui-on Leung ,  William McBride ,  Zhengxing Gu

Inventor： David Goldenberg ,  Hans Hansen ,  Shui-on Leung ,  William McBride ,  Zhengxing Gu

IPC: A61K49/14 ,  A61K51/00 ,  C07K7/06

CPC classification number: A61K51/1048 ,  A61K47/665 ,  A61K47/6879 ,  A61K51/1063 ,  A61K2039/505 ,  B82Y5/00 ,  C07K5/0215 ,  C07K5/1016 ,  C07K5/1019 ,  C07K7/06 ,  C07K16/18 ,  C07K16/3007 ,  C07K16/3046 ,  C07K16/44 ,  C07K16/468 ,  C07K2317/12 ,  C07K2317/13 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2319/00

Abstract: The present invention relates to targetable constructs which may be bound by a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds the targetable construct. The targetable construct comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable construct further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the targetable constructs and bi-specific antibodies or antibody fragments, as well as methods for using them.

Abstract translation: 本发明涉及可靶向的构建体，其可以由具有特异性结合靶组织的至少一个臂的双特异性抗体或抗体片段和至少一个特异性结合可靶向构建体的其它臂结合。 可靶向构建体包含载体部分，其包含或携带至少一个可被所述双特异性抗体或抗体片段的至少一个臂识别的表位。 可靶向构建物还包含一种或多种治疗剂或诊断剂或酶。 本发明提供用于产生可靶向构建体和双特异性抗体或抗体片段的构建体和方法，以及使用它们的方法。

公开(公告)号：US20050100543A1

公开(公告)日：2005-05-12

申请号：US10882151

申请日：2004-07-01

Applicant: Hans Hansen ,  William McBride ,  Zhengxing Qu

Inventor： Hans Hansen ,  William McBride ,  Zhengxing Qu

IPC: A61K20060101 ,  A61K39/395 ,  A61K47/48 ,  A61K51/08 ,  A61K51/10 ,  C07K16/28 ,  C07K16/30 ,  C07K16/44 ,  C12N9/00

CPC classification number: C07K16/2887 ,  A61K47/6897 ,  A61K51/1027 ,  A61K51/1048 ,  A61K51/109 ,  A61K2039/505 ,  B82Y5/00 ,  C07K16/3007 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/01

Abstract: Provided herein are targetable constructs that are multivalent carriers of bi-specific antibodies, i.e., each molecule of a targetable construct can serve as a carrier of two or more bi-specific antibodies. Also provided are targetable complexes formed by the association of a targetable construct with two or more bi-specific antibodies. The targetable constructs and targetable complexes of the invention are incorporated into biosensors, kits and pharmaceutical compositions, and are used in a variety of therapeutic and other methods.

Abstract translation: 本文提供作为双特异性抗体的多价载体的可靶向构建体，即可靶向构建体的每个分子可以用作两种或更多种双特异性抗体的载体。 还提供了通过可靶向构建体与两种或更多种双特异性抗体缔合形成的可靶向复合物。 将本发明的可靶向构建体和可靶向复合物掺入生物传感器，试剂盒和药物组合物中，并且以多种治疗和其它方法使用。

公开(公告)号：US20030101466A1

公开(公告)日：2003-05-29

申请号：US10262089

申请日：2002-09-30

Inventor： John Harvey Turner

IPC: A01K067/00

CPC classification number: A61K51/1048 ,  A01K67/0271 ,  A61K38/13 ,  A61K31/495 ,  A61K2300/00

Abstract: The invention relates to an animal model of cancer. The animal carries a tumour xenograft and is immunosuppressed by administration of cyclosporin and ketoconazole. The model is useful for studying cancer and treatment thereof.

Abstract translation: 本发明涉及癌症的动物模型。 动物携带肿瘤异种移植物，并通过施用环孢菌素和酮康唑进行免疫抑制。 该模型可用于研究癌症及其治疗。

公开(公告)号：US20020147997A1

公开(公告)日：2002-10-10

申请号：US09155237

申请日：1998-09-21

Inventor： JOHN HARVEY TURNER

IPC: A01K067/033 ,  A01K067/00 ,  G01N033/00

CPC classification number: A61K51/1048 ,  A01K67/0271 ,  A61K38/13 ,  A61K31/495 ,  A61K2300/00

Abstract: The invention relates to an animal model of cancer. The animal carries a tumor xenograft and is immunosuppressed by administration of cyclosporin and ketoconazole. The model is useful for studying cancer and treatment thereof.

Abstract translation: 本发明涉及癌症的动物模型。 动物携带肿瘤异种移植物，并通过施用环孢菌素和酮康唑进行免疫抑制。 该模型可用于研究癌症及其治疗。

公开(公告)号：US06458933B1

公开(公告)日：2002-10-01

申请号：US09314135

申请日：1999-05-19

Applicant: Hans J. Hansen

Inventor： Hans J. Hansen

IPC: C12P2108

CPC classification number: A61K51/1048 ,  A61K38/00 ,  A61K47/62 ,  A61K47/6893 ,  A61K51/0495 ,  A61K2039/507 ,  B82Y5/00 ,  C07K16/1045 ,  C07K16/14 ,  C07K16/18 ,  C07K16/242 ,  C07K16/2833 ,  C07K16/3007 ,  C07K16/4241 ,  C07K16/4258 ,  C07K16/4266 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/626

Abstract: Multivalent, multispecific molecules having at least one specificity for a pathogen and at least one specificity for the HLA class II invariant chain (Ii) are administered to induce clearance of the pathogen. In addition to pathogens, clearance of therapeutic or diagnostic agents, autoantibodies, anti-graft antibodies, and other undesirable compounds may be induced using the multivalent, multispecific molecules.

Abstract translation: 给予对病原体具有至少一种特异性和对HLA II类不变链（Ii）至少一种特异性的多价多特异性分子，以诱导病原体的清除。 除了病原体之外，还可以使用多价多特异性分子来诱导治疗或诊断剂，自身抗体，抗移植物抗体和其它不期望的化合物的清除。

公开(公告)号：US5703213A

公开(公告)日：1997-12-30

申请号：US193673

申请日：1994-02-07

Applicant: Jack R. Wands ,  Hiroshi Takahashi

Inventor： Jack R. Wands ,  Hiroshi Takahashi

IPC: A61K39/395 ,  A61K38/00 ,  A61K41/00 ,  A61K51/10 ,  C07K1/22 ,  C07K14/00 ,  C07K14/47 ,  C07K16/00 ,  C07K16/30 ,  C12N5/10 ,  C12N5/20 ,  C12N15/02 ,  C12P21/08 ,  C12R1/91 ,  G01N33/53 ,  G01N33/574 ,  G01N33/577 ,  C12N5/12 ,  C12N5/18

CPC classification number: C07K14/4748 ,  A61K41/0057 ,  A61K51/1048 ,  A61K51/1093 ,  C07K16/30 ,  A61K2123/00 ,  A61K38/00

Abstract: The present invention is directed to antibodies, and fragments thereof, which specifically bind the AF-20 and the XF-8 epitopes of adenocarcinoma cell antigen(s).

Abstract translation: 本发明涉及特异性结合腺癌细胞抗原的AF-20和XF-8表位的抗体及其片段。

公开(公告)号：US5635603A

公开(公告)日：1997-06-03

申请号：US352715

申请日：1994-12-05

Applicant: Hans J. Hansen ,  Shui-on Leung ,  Jerry Shevitz ,  Gary L. Griffiths ,  Seregulam V. Govindan

Inventor： Hans J. Hansen ,  Shui-on Leung ,  Jerry Shevitz ,  Gary L. Griffiths ,  Seregulam V. Govindan

IPC: G01N33/53 ,  A61K38/00 ,  A61K39/395 ,  A61K49/00 ,  A61K51/10 ,  C07H21/04 ,  C07K16/00 ,  C07K16/30 ,  C07K17/00 ,  C12N15/09 ,  C12P21/08 ,  C12R1/91 ,  G01N33/532 ,  G01N33/563 ,  G01N33/68

CPC classification number: G01N33/6857 ,  A61K51/1048 ,  A61K51/1069 ,  A61K51/1093 ,  C07K16/00 ,  C07K16/30 ,  C07K16/3007 ,  C07K16/3061 ,  G01N33/532 ,  A61K2121/00 ,  A61K2123/00 ,  A61K38/00

Abstract: The present invention relates to immunoconjugates comprising an antibody fragment which is covalently bound to a diagnostic or therapeutic principle through a carbohydrate moiety in the light chain variable region of the antibody fragment. The invention also relates to immunoconjugates comprising an antibody moiety that is an intact antibody containing a glycosylation site in the light chain variable domain which has been introduced into the antibody by mutating the nucleotide sequence encoding the light chain. The resultant immunoconjugates retain the immunoreactivity of the antibody fragment or intact antibody, and target the diagnostic or therapeutic principle to a target tissue where the diagnostic or therapeutic effect is realized. Thus, the invention contemplates the use of such immunoconjugates for diagnosis and immunotherapy. The invention further relates to methods for preparing such immunoconjugates.

Abstract translation: 本发明涉及包含通过抗体片段的轻链可变区中的碳水化合物部分与诊断或治疗原理共价结合的抗体片段的免疫缀合物。 本发明还涉及包含抗体部分的免疫缀合物，所述抗体部分是通过突变编码轻链的核苷酸序列而被引入抗体的包含轻链可变结构域中的糖基化位点的完整抗体。 所得的免疫偶联物保留抗体片段或完整抗体的免疫反应性，并将诊断或治疗原理靶向实现诊断或治疗效果的靶组织。 因此，本发明考虑使用这种免疫缀合物进行诊断和免疫治疗。 本发明还涉及制备这种免疫缀合物的方法。

公开(公告)号：US5601825A

公开(公告)日：1997-02-11

申请号：US452131

申请日：1995-05-26

Applicant: Hans J. Hansen ,  Gary L. Griffiths ,  Anastasia Lentine-Jones ,  David M. Goldenberg

Inventor： Hans J. Hansen ,  Gary L. Griffiths ,  Anastasia Lentine-Jones ,  David M. Goldenberg

IPC: A61K38/00 ,  A61K31/00 ,  A61K38/22 ,  A61K38/43 ,  A61K39/395 ,  A61K47/48 ,  A61K51/10 ,  A61K51/12 ,  A61P31/00 ,  A61P35/00 ,  A61P35/02 ,  C07K14/435 ,  C07K16/06 ,  C07K16/10 ,  C07K16/18 ,  C07K16/30 ,  G01N33/534 ,  G01N33/68 ,  C07K16/20 ,  C07K19/00

CPC classification number: A61K51/10 ,  A61K47/48523 ,  A61K47/48569 ,  A61K51/1018 ,  A61K51/1048 ,  A61K51/1093 ,  A61K51/1282 ,  C07K16/065 ,  C07K16/1063 ,  C07K16/30 ,  G01N33/534 ,  G01N33/6857 ,  A61K2121/00 ,  A61K2123/00 ,  A61K38/00

Abstract: Provided are conjugates useful in cancer or infectious disease therapy. The conjugate is a drug or modified toxin which is a native toxin devoid of a functioning receptor binding domain and a protein which reacts with a substance associated with a targeted cell or pathogen. The targeted substance internalizes the conjugate into the cell cytoplasm, and the kills the cell. The protein prior to conjugation has at least one mercapto group which becomes a site for conjugation to the toxin or drug. Also provided are methods of therapy, methods for producing the conjugate and pharmaceuticals compositions of the conjugates.

Abstract translation: 提供可用于癌症或感染性疾病治疗的缀合物。 缀合物是药物或修饰的毒素，其是没有功能受体结合结构域的天然毒素和与靶向细胞或病原体相关的物质发生反应的蛋白质。 靶向物质将结合物内化为细胞质，杀死细胞。 缀合前的蛋白质具有至少一个巯基，其成为与毒素或药物缀合的位点。 还提供了治疗方法，生产缀合物的方法和缀合物的药物组合物。